Kazia Therapeutics Limited - ROE
KZIA
Price:
$13.86
Market Cap:
$32.00M
Kazia Therapeutics Limited is a biotechnology firm primarily dedicated to creating pharmaceutical treatments for cancer. Its leading therapeutic asset is Paxalisib, a distinctive small molecule that can penetrate the brain and works by inhibiting the PI3K/Akt/mTor pathway, showing promise as a potential remedy for glioblastoma. The company is also progressing with EVT801, an experimental medication being investigated for its efficacy against various cancer types. Incorporated in 1994, the entity operated under the name Novogen Limited until its rebranding to Kazia Therapeutics Limited in November 2017. The company's main operations are based in Sydney, Australia.
Industry
Biotechnology
IPO Date
1999-01-06
Stock Exchange
NASDAQ
Ticker
KZIA
PE Ratio
[-1.84]
ROE
[-116.86%]
Current Ratio
[2.87]
Dividend Yield
[0%]
Enterprise Value
[-37291703.10]
Dividend History
The ROE as of June 2026 (TTM) for Kazia Therapeutics Limited (KZIA) is -116.86%
According to Kazia Therapeutics Limited’s latest financial reports and current stock price. The company's current ROE is -116.86%. This represents a change of -185.43% compared to the average of 136.78% of the last 4 quarters.
Kazia Therapeutics Limited (KZIA) Historical ROE (quarterly & annually)
How has KZIA ROE performed in the past?
The mean historical ROE of Kazia Therapeutics Limited over the last ten years is -8.19%. The current -116.86% ROE has changed 1.33% with respect to the historical average. Over the past ten years (40 quarters), KZIA's ROE was at its highest in in the December 2024 quarter at 274.56%. The ROE was at its lowest in in the June 2014 quarter at -292.00%.
Average
-8.19%
Median
-38.83%
Minimum
-169.84%
Maximum
267.33%
Kazia Therapeutics Limited (KZIA) ROE by Quarter and Year
Discovering the peaks and valleys of Kazia Therapeutics Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 515.30%
Maximum Annual ROE = 267.33%
Minimum Annual Increase = -257.40%
Minimum Annual ROE = -169.84%
| Year | ROE | Change |
|---|---|---|
| 2025 | 249.39% | -6.71% |
| 2024 | 267.33% | -257.40% |
| 2023 | -169.84% | 24.08% |
| 2022 | -136.88% | 515.30% |
| 2021 | -22.25% | -74.80% |
| 2020 | -88.27% | 22.00% |
| 2019 | -72.35% | 130.53% |
| 2018 | -31.38% | -25.47% |
| 2017 | -42.11% | 18.47% |
| 2016 | -35.55% | 122.43% |
Kazia Therapeutics Limited (KZIA) Average ROE
How has KZIA ROE performed in the past?
The current ROE of Kazia Therapeutics Limited (KZIA) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
115.63%
5-year avg
37.55%
10-year avg
-8.19%
Kazia Therapeutics Limited (KZIA) ROE vs. Peers
How is KZIA’s ROE compared to its peers?
Kazia Therapeutics Limited’s ROE is greater than Can-Fite BioPharma Ltd. (-141.01%), greater than CNS Pharmaceuticals, Inc. (-238.69%), greater than Silo Pharma, Inc. (-88.41%), greater than Soligenix, Inc. (-246.04%), greater than Biodexa Pharmaceuticals Plc (-55.81%), greater than Clearmind Medicine Inc. (-138.23%), greater than InMed Pharmaceuticals Inc. (-72.72%), greater than GRI Bio, Inc. (-199.52%), greater than Oragenics, Inc. (-177.32%), less than Titan Pharmaceuticals, Inc. (1.94%),
| Company | ROE | Market cap |
|---|---|---|
| -141.01% | $1.60M | |
| -238.69% | $2.70M | |
| -88.41% | $5.54M | |
| -246.04% | $4.12M | |
| -55.81% | $2.28M | |
| -138.23% | $3.13M | |
| -72.72% | $2.70M | |
| -199.52% | $168.88K | |
| -177.32% | $2.48M | |
| 1.94% | $3.11M |
Build a custom stock screener for Kazia Therapeutics Limited (KZIA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kazia Therapeutics Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Kazia Therapeutics Limited (KZIA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Kazia Therapeutics Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Kazia Therapeutics Limited's ROE?
How is the ROE calculated for Kazia Therapeutics Limited (KZIA)?
What is the highest ROE for Kazia Therapeutics Limited (KZIA)?
What is the 3-year average ROE for Kazia Therapeutics Limited (KZIA)?
What is the 5-year average ROE for Kazia Therapeutics Limited (KZIA)?
How does the current ROE for Kazia Therapeutics Limited (KZIA) compare to its historical average?